It has been developed by Synvista Therapeutics, Inc for the treatment of diabetic kidney disease.Pimagedine HCl is an advanced glycation end products inhibitor which manages diabetic nephropathy, either alone or in combination with other therapies. It is beneficial in treating patients with diabetic nephropathy. (en)
Pimagedine reportedly inhibits the formation of glycosylated proteins (advanced glycosylation end-products) and has other actions including inhibition of aldose reductase. (en)